Business Context and Reporting Period
This Form 8-K Current Report was filed by Palisade Bio, Inc. on August 19, 2021. The filing discloses the entry into a definitive material agreement and the unregistered sale of equity securities to Yuma Regional Medical Center.
Key Financial Metrics and Transaction Details
- Total Purchase Price: $5,209,141.20
- Common Stock Issued: 1,509,896 shares
- Warrant Issued: Right to purchase up to 377,474 shares
- Purchase Price per Share: $3.45
- Warrant Exercise Price: $3.45 (subject to adjustments)
- Warrant Term: 5 years
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Transaction Structure
The Company entered into a Securities Purchase Agreement with Yuma Regional Medical Center, an existing stockholder. The transaction was executed under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D as a private placement. The Company agreed to file registration statements for the resale of the shares and warrant-issuable shares, bearing all registration expenses except for the Investor's legal counsel fees.
Management Commentary, Risks, and Related Parties
Robert J. Trenschel, D.O., serves as a member of Palisade Bio's board of directors and is the President and CEO of the Investor, Yuma Regional Medical Center. The filing states that Dr. Trenschel has no pecuniary interest in the securities owned by the Investor. The agreement includes customary representations and warranties, which are qualified by confidential disclosures and specific materiality standards applicable to the contracting parties.
Investor Verification Checklist
- Verify the full terms of the Securities Purchase Agreement (Exhibit 4.1) and Warrant (Exhibit 4.2) for specific adjustment mechanisms and covenants.
- Confirm the status of the registration statement required for the resale of the shares.
- Review the Company's latest audited financial statements to assess liquidity and cash runway, as this 8-K does not contain financial performance data.
- Monitor the Company's capital structure for potential dilution from the warrant exercise.